

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 December 2024 (12.12.2024)



(10) International Publication Number
WO 2024/254490 A1

(51) International Patent Classification:

C07D 487/04 (2006.01) A61P 35/00 (2006.01)
C07D 519/00 (2006.01) A61K 31/519 (2006.01)

(21) International Application Number:

PCT/US2024/033065

(22) International Filing Date:

07 June 2024 (07.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/472,105 09 June 2023 (09.06.2023) US
63/608,086 08 December 2023 (08.12.2023) US
63/635,197 17 April 2024 (17.04.2024) US

(71) Applicant: ACRIVON THERAPEUTICS, INC.

[US/US]; 480 Arsenal Way, Suite 100, Watertown, Massachusetts 02472 (US).

(72) Inventors: JÖNSSON, Hans Mattias; c/o Red Glead Discovery AB, Medicon Village, 223 81 Lund (SE). RA-

JABI, Nima; c/o Red Glead Discovery AB, Medicon Village, 223 81 Lund (SE). PAULSEN, Filip Alexander; c/o Red Glead Discovery AB, Medicon Village, 223 81 Lund (SE). ÖHLANDER, Andrea; c/o Red Glead Discovery AB, Medicon Village, 223 81 Lund (SE). BORGSTRÖM, Björn; c/o Red Glead Discovery AB, Medicon Village, 223 81 Lund (SE). AF ROSENSCHÖLD, Magnus Munck; c/o Red Glead Discovery AB, Medicon Village, 223 81 Lund (SE). BRIMERT, Lars Thomas; c/o Red Glead Discovery AB, Medicon Village, 223 81 Lund (SE). WIGERUP, Caroline Maria; c/o Acrivon Therapeutics, Inc., 480 Arsenal Way, Suite 100, Watertown, Massachusetts 02472 (US). VAN DUZER, John Henry; c/o Acrivon Therapeutics, Inc., 480 Arsenal Way, Suite 100, Watertown, Massachu-

setts 02472 (US). PROIA, David; c/o Acrivon Therapeutics, Inc., 480 Arsenal Way, Suite 100, Watertown, Massachusetts 02472 (US). SHI, Lei; c/o Acrivon Therapeutics, Inc., 480 Arsenal Way, Suite 100, Watertown, Massachusetts 02472 (US). NILSSON, Åsa Helén; c/o Acrivon Therapeutics, Inc., 480 Arsenal Way, Suite 100, Watertown, Massachusetts 02472 (US).

(74) Agent: CONTRACTOR, Alisha A. et al.; CHOATE, HALL & STEWART LLP, Two International Place, Boston, Massachusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE

(57) Abstract: Pyrazolo-pyrimidinone compounds of formula I: for use in methods of inhibiting Wee1A kinase or both Wee1A kinase and Myt1 kinase.

formula I:



WO 2024/254490 A1

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*